Table 1 Baseline characteristics by treatment: unadjusted n and adjusted percentages with propensity scores, and median [IQR] follow-up.
All | Radical prostatectomy | Brachytherapy | External radiotherapy | Adjusted p-valuea | |
|---|---|---|---|---|---|
Participants | 704 | 192 | 317 | 195 | |
Unadjusted n (adjusted %) | |||||
Age | 0.484 | ||||
≤ 65 years | 265 (33.0%) | 114 (32.8%) | 113 (33.8%) | 38 (31.7%) | |
66 – 70 years | 222 (40.2%) | 61 (47.6%) | 100 (37.4%) | 61 (37.6%) | |
≥ 71 years | 216 (26.8%) | 16 (19.6%) | 104 (28.8%) | 96 (30.8%) | |
Missing | 1 (0.1%) | 1 (0.5%) | 0 | 0 | |
PSA | 0.590 | ||||
< 10 | 603 (98.0%) | 155 (92.4%) | 294 (89.6%) | 154 (92.4%) | |
[10, 20] | 100 (1.9%) | 36 (7.6%) | 23 (10.4%) | 41 (7.6%) | |
Missing | 1 (0.1%) | 1 (0.5%) | 0 | 0 | |
Gleason score | 0.038 | ||||
≤ 6 | 563 (93.7%) | 114 (92.6%) | 308 (96.3%) | 141 (90.0%) | |
7 | 139 (6.3%) | 76 (7.4%) | 9 (3.7%) | 54 (10.0%) | |
Missing | 2 (0.3%) | 2 (1.0%) | 0 | 0 | |
Clinical T Stage | 0.439 | ||||
≤ T2a | 651 (97.6%) | 175 (98.6%) | 307 (96.8%) | 169 (97.9%) | |
T2b | 47 (2.4%) | 13 (1.4%) | 9 (3.2%) | 25 (2.1%) | |
Missing | 6 (0.9%) | 4 (2.1%) | 1 (0.3%) | 1 (0.5%) | |
Risk group | 0.756 | ||||
Low | 482 (86.5%) | 91 (88.3%) | 283 (85.0%) | 108 (87.1%) | |
Intermediate | 222 (13.5%) | 101 (11.7%) | 34 (15.0%) | 87 (12.9%) | |
Neoadjuvant hormonal treatment | 0.764 | ||||
No | 521 (81.4%) | 175 (78.6%) | 212 (82.7%) | 134 (82.0%) | |
Yes | 183 (18.6%) | 17 (21.4%) | 105 (17.5%) | 61 (18.4%) | |
Adjusted median [IQR] follow-up, years | |||||
Vital status | 10.0 [10.0, 10.0] | 10.0 [10.0, 10.0] | 10.0 [10.0, 10.0] | ||
Biochemical recurrence | 10.0 [9.0, 10.0] | 9.9 [9.1, 10.0] | 10.0 [8.6, 10.0] | ||
